Venture investor and healthcare operating executive with experience sourcing and scaling clinical-stage life-science companies, advising boards and structuring early-to-growth-stage financings. Megan J. Lottier brings cross-functional expertise in commercial strategy, regulatory pathway planning and fundraising support, often partnering with founders and later-stage sponsors to de-risk clinical programs and accelerate go-to-market execution in North America and Europe.
Venture investor and healthcare operating executive with experience sourcing and scaling clinical-stage life-science companies, advising boards and structuring early-to-growth-stage financings. Megan J. Lottier brings cross-functional expertise in commercial strategy, regulatory pathway planning and fundraising support, often partnering with founders and later-stage sponsors to de-risk clinical programs and accelerate go-to-market execution in North America and Europe.
Specializes in early-to-growth-stage life‑science investments, prioritizing clinical-stage biotech and healthtech where commercial and regulatory strategy materially de-risks programs. Employs a hands-on, partnership-driven approach—working with founders and sponsors to align clinical endpoints, regulatory pathways and go‑to-market plans—while structuring financings to extend runways and preserve optionality. Investment selection emphasizes differentiated science with clear clinical inflection points, predictable reimbursement pathways, and experienced management teams. Time horizon is patient capital through clinical milestones; risk management combines staged capital, board-level governance and selective follow‑on reserves to protect value and accelerate North American and European market entry.
Specializes in early-to-growth-stage life‑science investments, prioritizing clinical-stage biotech and healthtech where commercial and regulatory strategy materially de-risks programs. Employs a hands-on, partnership-driven approach—working with founders and sponsors to align clinical endpoints, regulatory pathways and go‑to-market plans—while structuring financings to extend runways and preserve optionality. Investment selection emphasizes differentiated science with clear clinical inflection points, predictable reimbursement pathways, and experienced management teams. Time horizon is patient capital through clinical milestones; risk management combines staged capital, board-level governance and selective follow‑on reserves to protect value and accelerate North American and European market entry.
| Trades 1186 | Longs Won 804/1186 67% | Profit Factor 54.43 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $2.6M |
| Average Win $516,940.56 | Best Trade (Jul 14) $75.35M | Sharpe Ratio -10.29 |
| Average Loss -$19,988.86 | Worst Trade (Mar 31) -$359,123.37 | Z-Score 14.54 (100%) |
| Commissions $0 | Avg. Trade Length 1y 8m 1d | Expectancy $344,000.39 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 76,923 | 69,231 | 61,538 | 53,846 | 46,154 | 38,462 | 30,769 | 23,077 | 15,385 | 7,692 |